COLOPLAST SP.ADR 1/10 DK1 (CBH) - Total Liabilities
Based on the latest financial reports, COLOPLAST SP.ADR 1/10 DK1 (CBH) has total liabilities worth €34.99 Billion EUR (≈ $40.91 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore COLOPLAST SP.ADR 1/10 DK1 (CBH) net asset momentum to track the company's year-over-year net asset growth rate.
COLOPLAST SP.ADR 1/10 DK1 - Total Liabilities Trend (2021–2024)
This chart illustrates how COLOPLAST SP.ADR 1/10 DK1's total liabilities have evolved over time, based on quarterly financial data. See COLOPLAST SP.ADR 1/10 DK1 (CBH) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
COLOPLAST SP.ADR 1/10 DK1 Competitors by Total Liabilities
The table below lists competitors of COLOPLAST SP.ADR 1/10 DK1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cipla Limited
NSE:CIPLA
|
India | Rs71.39 Billion |
|
Smith & Nephew SNATS Inc
NYSE:SNN
|
USA | $5.17 Billion |
|
LLOYDS METALS AND ENERGY LTD.
NSE:LLOYDSME
|
India | Rs273.84 Billion |
|
Samsung Heavy Industries
KO:010140
|
Korea | ₩10.85 Trillion |
|
SK Telecom Co Ltd
KO:017670
|
Korea | ₩17.15 Trillion |
|
Zhejiang Satellite Petrochemical Co Ltd
SHE:002648
|
China | CN¥39.17 Billion |
|
GRAB HOLDINGS LTD CL.A
F:A6I
|
Germany | €5.23 Billion |
|
Guardant Health Inc
NASDAQ:GH
|
USA | $2.10 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down COLOPLAST SP.ADR 1/10 DK1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of COLOPLAST SP.ADR 1/10 DK1.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how COLOPLAST SP.ADR 1/10 DK1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for COLOPLAST SP.ADR 1/10 DK1 (2021–2024)
The table below shows the annual total liabilities of COLOPLAST SP.ADR 1/10 DK1 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | €30.13 Billion ≈ $35.23 Billion |
-2.36% |
| 2023-09-30 | €30.86 Billion ≈ $36.08 Billion |
+5.85% |
| 2022-09-30 | €29.15 Billion ≈ $34.08 Billion |
+279.96% |
| 2021-09-30 | €7.67 Billion ≈ $8.97 Billion |
-- |
About COLOPLAST SP.ADR 1/10 DK1
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, wh… Read more